351 related articles for article (PubMed ID: 11183904)
1. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs.
Weycker D; Richardson E; Oster G
Am J Manag Care; 2000 Jul; 6(10 Suppl):S526-35. PubMed ID: 11183904
[TBL] [Abstract][Full Text] [Related]
2. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
5. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
Giglio ND; Cane AD; Micone P; Gentile A
Vaccine; 2010 Mar; 28(11):2302-10. PubMed ID: 20064478
[TBL] [Abstract][Full Text] [Related]
7. Streptococcus pneumoniae-related illnesses in young children: secular trends and regional variation.
Poehling KA; Szilagyi PG; Edwards K; Mitchel E; Barth R; Hughes H; Lafleur B; Schaffer SJ; Schwartz B; Griffin MR
Pediatr Infect Dis J; 2003 May; 22(5):413-8. PubMed ID: 12792380
[TBL] [Abstract][Full Text] [Related]
8. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
De Wals P; Black S; Borrow R; Pearce D
Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
[TBL] [Abstract][Full Text] [Related]
9. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
Silfverdal SA; Berg S; Hemlin C; Jokinen I
Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
11. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
Lieu TA; Ray GT; Black SB; Butler JC; Klein JO; Breiman RF; Miller MA; Shinefield HR
JAMA; 2000 Mar; 283(11):1460-8. PubMed ID: 10732936
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?
van Kempen MJ; Vermeiren JS; Vaneechoutte M; Claeys G; Veenhoven RH; Rijkers GT; Sanders EA; Dhooge IJ
Int J Pediatr Otorhinolaryngol; 2006 Feb; 70(2):275-85. PubMed ID: 16140397
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.
Blank PR; Szucs TD
Vaccine; 2012 Jun; 30(28):4267-75. PubMed ID: 22521287
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
[TBL] [Abstract][Full Text] [Related]
15. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of pneumococcal conjugate vaccination in Finland.
Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
[TBL] [Abstract][Full Text] [Related]
19. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.
Grijalva CG; Poehling KA; Nuorti JP; Zhu Y; Martin SW; Edwards KM; Griffin MR
Pediatrics; 2006 Sep; 118(3):865-73. PubMed ID: 16950975
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
Giorgi-Rossi P; Merito M; Borgia P
Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
